Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
5(45%)
Results Posted
40%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
4
36%
Ph phase_2
2
18%
Ph phase_1
5
45%

Phase Distribution

5

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
5(45.5%)
Phase 2Efficacy & side effects
2(18.2%)
N/ANon-phased studies
4(36.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(5)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Active, not recruiting3
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (45.5%)
Phase 22 (18.2%)
N/A4 (36.4%)

Trials by Status

recruiting218%
completed545%
active_not_recruiting327%
terminated19%

Recent Activity

5 active trials
Showing 5 of 11
active_not_recruitingphase_2

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT04899908
recruitingphase_2

Stereotactic Radiotherapy (SBRT) of Lung Metastasis

NCT01803542
recruitingphase_1

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

NCT06238921
active_not_recruitingphase_1

Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA

NCT02685332
active_not_recruitingnot_applicable

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

NCT03391362
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04899908Phase 2

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Active Not Recruiting
NCT01803542Phase 2

Stereotactic Radiotherapy (SBRT) of Lung Metastasis

Recruiting
NCT06238921Phase 1

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Recruiting
NCT02685332Phase 1

Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA

Active Not Recruiting
NCT03391362Not Applicable

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Active Not Recruiting
NCT02052648Phase 1

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Completed
NCT01859221Not Applicable

Radiotherapy for Oligometastatic Prostate Cancer

Completed
NCT01656486Not Applicable

Stereotactic Radiation to Decrease Pancreatic Secretions

Completed
NCT02110992Phase 1

Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

Terminated
NCT00807339Not Applicable

CyberKnife for Unresectable Renal Tumors

Completed
NCT01668134Phase 1

Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma

Completed

All 11 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
11